Skip to main content

Table 1 Patient characteristics by BDX008 classification for all patients and by BRAF status

From: Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations

  All patients (N = 71) BRAF WT (N = 39) BRAF MUT (N = 25)
BDX008+ (N = 30) BDX008- (N = 41) BDX008+ (N = 15) BDX008- (N = 24) BDX008+ (N = 12) BDX008- (N = 13)
Age
 Median (Range) 59 (28–86) 66 (32–80) 59 (34–86) 61 (44–80) 52 (29–69) 67 (32–78)
Gender, n (%)
 Female 16 (53) 19 (46) 8 (53) 10 (42) 7 (58) 7 (54)
 Male 14 (47) 22 (54) 7 (47) 14 (58) 5 (42) 6 (46)
BRAF Status, n (%)
 Mutation 12 (40) 13 (32) 0 (0) 0 (0) 12 (100) 13 (100)
 Wild Type 15 (50) 24 (59) 15(100) 24(100) 0 (0) 0 (0)
 NA 3 (10) 4 (10) 0 (0) 0 (0) 0 (0) 0 (0)
Line of Therapy with anti-PD-1, n (%)
 1st 1 (3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
 2nd 4(13) 13 (32) 3 (20) 9 (38) 0 (0) 3 (23)
 3rd 17(57) 16 (39) 11 (73) 11 (46) 5 (42) 3 (23)
 4th 4 (13) 10 (24) 1 (7) 4 (17) 3 (25) 6 (46)
 5th and higher 4 (13) 2 (5) 0 (0) 0 (0) 4 (33) 1(8)
Targeted therapy, n (%)
 No 18 (60) 28 (68) 14 (93) 22 (92) 2 (15) 1 (8)
 Yes 12 (40) 13 (32) 1 (7) 2 (8) 11 (85) 11 (92)
Anti-PD-1 agent, n (%)
 Nivolumab 9 (30) 15 (37) 6 (40) 10 (42) 1 (8) 4 (31)
 Pembrolizumab 21 (70) 26 (62) 9 (60) 14 (58) 11 (92) 9 (69)
NLR, n (%)
 <5 25 (83) 19 (46) 14 (93) 12 (50) 8 (67) 5 (38)
 ≥5 5 (17) 22 (54) 1 (7) 12 (50) 4 (33) 8 (62)
LDH
 Median (in IU/l) 402 617 379 525 416 728
 NA, n (%) 5 (17) 2 (5) 3 (20) 2 (8) 2 (17) 0 (0)
 <2ULNa, n (%) 22 (73) 21 (51) 12 (80) 15 (63) 7 (58) 5 (38)
 2ULNa, n (%) 3 (10) 18 (44) 0 (0) 7 (29) 3 (25) 8 (62)
Melanoma Type, n (%)
 cutaneous 22 (73) 24 (59) 11 (73) 14 (58) 10 (83) 9 (69)
 mucosal 2 (7) 1 (2) 2 (13) 1 (4) 0 (0) 0 (0)
 SPI 2 (7) 2 (5) 1 (7) 1 (4) 1 (8) 0 (0)
 uveal 2 (7) 4 (10) 0 (0) 3 (13) 0 (0) 0 (0)
 NA 2 (7) 10 (24) 1 (7) 5 (21) 1 (8) 4 (31)
  1. aULN upper limit of normal (333 IU/l)